Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VISEN PharmaceuticalsFRA:T06 7 PS Ratio is 50.24 as of Aug. 29, 2026, which is 100% below its 10-year median of 12,530.00. GuruFocus rates FRA:T06 with a GF Score™ of 7/100. The stock has 5 warning signs investors should review. Among 951 Drug Manufacturers companies, VISEN Pharmaceuticals ranks worse than 100% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, VISEN Pharmaceuticals's share price is €2.06.
VISEN Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was €0.04. Hence, VISEN Pharmaceuticals's PS Ratio for today is 50.24.
Good Sign:
VISEN Pharmaceuticals stock PS Ratio (=9990) is close to 1-year low of 9550.
The historical rank and industry rank for VISEN Pharmaceuticals's PS Ratio or its related term are showing as below:
FRA:T06'
s PS Ratio Range Over the Past 10 Years
Min: 54.29 Med: 12530 Max: 18860
Current: 54.29
During the past 4 years, VISEN Pharmaceuticals's highest PS Ratio was 18860.00. The lowest was 54.29. And the median was 12530.00.
FRA:T06's PS Ratio is ranked worse than 100% of 951
companies
in the Drug Manufacturers industry
Industry Median: 2.38
vs FRA:T06: 54.29
VISEN Pharmaceuticals (FRA:T06) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, VISEN Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VISEN Pharmaceuticals PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, VISEN Pharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where VISEN Pharmaceuticals's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
VISEN Pharmaceuticals's Share Price of today is €2.06.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. VISEN Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was €0.04.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
VISEN Pharmaceuticals (FRA:T06) has a PS Ratio of 50.24 as of Aug. 29, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on VISEN Pharmaceuticals and its competitors. This is 100% below median its historical median of 12,530.00. Over the past decade, VISEN Pharmaceuticals' PS Ratio has ranged from 54.29 to 18,860.00. According to the industry distribution chart, VISEN Pharmaceuticals ranks #951 out of 951 companies in the Drug Manufacturers industry.
Is VISEN Pharmaceuticals' PS Ratio too high?
VISEN Pharmaceuticals' current PS Ratio of 50.24 is 100% below median its 10-year median of 12,530.00. Over the past 10 years, this metric has ranged from a low of 54.29 to a high of 18,860.00. The Drug Manufacturers industry median PS Ratio is 2.38. VISEN Pharmaceuticals' value of 50.24 is 2010.9% above this industry median. Based on the distribution chart, VISEN Pharmaceuticals ranks #951 out of 951 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, VISEN Pharmaceuticals has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does VISEN Pharmaceuticals' PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, VISEN Pharmaceuticals ranks #951 out of 951 companies for PS Ratio. This places VISEN Pharmaceuticals in the lower half of its industry. The industry median PS Ratio is 2.38. VISEN Pharmaceuticals' value of 50.24 is 2010.9% above this benchmark. Historically, VISEN Pharmaceuticals' own PS Ratio has ranged from 54.29 to 18,860.00 over the past decade. While the company's 10-year median is 12,530.00 vs. the industry median of 2.38, VISEN Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.38, based on 951 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VISEN Pharmaceuticals's current PS Ratio of 50.24 is 2010.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on VISEN Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VISEN Pharmaceuticals's current PS Ratio is 50.24, which is 100% below median its own 10-year median of 12,530.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VISEN Pharmaceuticals stock overvalued right now?
VISEN Pharmaceuticals (FRA:T06) has a current PS Ratio of 50.24. The current PS Ratio is 50.24, which is 100% below median its 10-year median of 12,530.00 and 2010.9% above the Drug Manufacturers industry median of 2.38. VISEN Pharmaceuticals' overall GF Score™ is 7/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For VISEN Pharmaceuticals (FRA:T06), the current PS Ratio is 50.24 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China. It has one Core Product and two other pipeline drug candidates. Its Core Product, lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency (PGHD), a common short stature in patients aged under 18 caused by insufficient growth hormone. TransCon CNP (navepegritide), one of its key drug candidates, is a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia (ACH), a short-limbed dwarfism that results in severe skeletal complications and comorbidities.
7GF Score
Get the complete analysis for FRA:T06
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:T06 has been successfully added to your 
